
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning</strong></summary>
            <div>
                <ul><li>Authors: David Fudman, Ryan A. McConnell, Christina Ha, Siddharth Singh</li><li>Journal: Clinical Gastroenterology and Hepatology</li><li>Publication Date: Accepted June 7, 2024</li><li>Focus: Practical use of newer advanced IBD therapies, real-world effectiveness &amp; safety, dosing &amp; monitoring, special situations (pregnancy, comorbidities, ASUC, perioperative).</li><li>Positioning: Integration of medication effectiveness &amp; safety w/ individual patient risk &amp; preferences.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What is the recommended washout period for ozanimod before conception?</li><li>2. Which JAK inhibitor is approved for both UC and CD?</li><li>3. What is the induction dose of upadacitinib for UC?</li><li>4. Which IL-23 antagonist has shown superiority to ustekinumab in clinical trials for CD?</li><li>5. What baseline assessments are recommended before starting S1PR modulators?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>JAK Inhibitors (JAKi)</strong></summary>
            <div>
                <ul><li>Oral small molecule drugs inhibiting transcription of pro-inflammatory cytokines.</li><li>Tofacitinib: Primarily inhibits JAK1 &amp; JAK3, approved for UC in 2018.</li><li>Upadacitinib: Primarily inhibits JAK1, approved for UC in 2022 &amp; CD in 2023.</li></ul>
                
        <details>
            <summary><strong>Real-World Effectiveness</strong></summary>
            <div>
                <ul><li>Tofacitinib: ≈ efficacy in real-world cohorts similar to clinical trials.</li><li>Upadacitinib: Limited real-world data, but high rates of clinical response &amp; remission in UC.</li><li>Upadacitinib may be more effective than tofacitinib in UC.</li></ul>
                
        <details>
            <summary><strong>Tofacitinib Details</strong></summary>
            <div>
                <ul><li>Systematic review: 2/3 patients achieved response, 1/3 remission within 8 weeks.</li><li>Higher rates in biologic-naïve patients.</li><li>May be more effective than vedolizumab in UC w/ prior TNF antagonist failure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Upadacitinib Details</strong></summary>
            <div>
                <ul><li>&gt;80% clinical response in some UC cohorts.</li><li>64% CD patients achieved clinical response, 27% remission @ 3 months (TNF antagonist, vedolizumab, ustekinumab failure).</li><li>May be more effective in colon-dominant CD &amp; perianal disease.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dosing and Onset of Action</strong></summary>
            <div>
                <ul><li>Efficacy &amp; safety are dose-dependent → lowest effective dose is optimal.</li><li>Rapid onset of action: clinical improvement w/in 1-3 days of starting therapy.</li><li>Upadacitinib can reduce abdominal pain &amp; stool frequency w/in 1 week.</li></ul>
                
        <details>
            <summary><strong>Tofacitinib Dosing</strong></summary>
            <div>
                <ul><li>Induction: 10mg twice daily (or 22mg ER daily) for 8 weeks.</li><li>Maintenance: 10mg twice daily or 5mg twice daily (or 11mg ER daily).</li><li>Dose de-escalation: Up to 50% lose response on de-escalation to 5mg twice daily.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Upadacitinib Dosing</strong></summary>
            <div>
                <ul><li>Induction: 45mg daily for 8 weeks (UC) or 12 weeks (CD).</li><li>Maintenance: 15mg or 30mg daily (UC &amp; CD).</li><li>30mg daily may be more effective, esp. w/ prior TNF antagonist failure.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Safety</strong></summary>
            <div>
                <ul><li>FDA black-box warnings: ↑ risk of mortality, MACE, thrombosis, malignancy, serious infections.</li><li>ORAL Surveillance trial (RA patients): ↑ rates of MACE, malignancy, VTE, serious infection, herpes zoster w/ tofacitinib.</li><li>No ↑ risk of MACE, VTE, or malignancy observed in IBD patients treated w/ tofacitinib or upadacitinib in long-term follow-up.</li></ul>
                
        <details>
            <summary><strong>Herpes Zoster Risk</strong></summary>
            <div>
                <ul><li>↑ risk of herpes zoster reactivation in dose-dependent manner, esp. w/ corticosteroids.</li><li>All patients receiving JAKi should receive 2-dose recombinant herpes zoster vaccine.</li><li>Avoid live vaccines while taking JAKi.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Acne</strong></summary>
            <div>
                <ul><li>Common adverse effect, particularly w/ upadacitinib @ higher doses (≈20%).</li><li>Upadacitinib associated w/ 4.8x higher odds of acne vs. placebo.</li><li>Topical therapies (clindamycin + benzoyl peroxide) or systemic antibiotics may be required.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Special Situations</strong></summary>
            <div>
                <ul><li>Therapeutic drug monitoring: Not warranted due to strong correlation between dose &amp; exposure.</li><li>Pregnancy &amp; lactation: Avoid in pregnancy (discontinue 4 weeks prior to conception) &amp; breastfeeding.</li><li>Acute severe UC: Rapid onset of action makes JAKis potential therapies for hospitalized patients.</li></ul>
                
        <details>
            <summary><strong>Perioperative Management</strong></summary>
            <div>
                <ul><li>Perioperative JAKi use not associated w/ ↑ risk of adverse outcomes in UC patients undergoing colectomy.</li><li>ACR/AAHKS guideline: withhold JAKis for 3 days prior to joint surgery; may be reasonable to extrapolate to elective surgery in IBD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Extraintestinal Manifestations</strong></summary>
            <div>
                <ul><li>JAKis approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis.</li><li>Useful in patients w/ comorbid inflammatory peripheral arthritis or axial spondyloarthropathies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Interleukin-23 Antagonists</strong></summary>
            <div>
                <ul><li>Monoclonal antibodies targeting p19 subunit of IL-23.</li><li>Risankizumab: Approved for moderate-severe CD.</li><li>Mirikizumab: Approved for moderate-severe UC.</li></ul>
                
        <details>
            <summary><strong>Effectiveness</strong></summary>
            <div>
                <ul><li>Risankizumab: Real-world effectiveness confirmed in cohort studies.</li><li>Mirikizumab: Significantly higher proportion achieved clinical response, remission, &amp; endoscopic remission vs. placebo.</li><li>Guselkumab: Phase 3 data awaited, but phase 2 trial showed higher rates of clinical &amp; endoscopic outcomes vs. placebo.</li></ul>
                
        <details>
            <summary><strong>Risankizumab Details</strong></summary>
            <div>
                <ul><li>SEQUENCE trial: Risankizumab superior to ustekinumab in achieving clinical remission @ week 24 (59% vs. 40%) &amp; endoscopic remission @ week 48 (32% vs. 16%) in CD.</li><li>INSPIRE &amp; COMMAND trials: Efficacious for biologic-naïve &amp; biologic-exposed UC patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mirikizumab Details</strong></summary>
            <div>
                <ul><li>LUCENT-1 &amp; LUCENT-2 trials: ≈40% patients failed prior biologic or tofacitinib.</li><li>Week 12: clinical response (64% vs. 42%), clinical remission (24% vs. 15%), endoscopic remission (36% vs. 21%).</li><li>VIVID-1 trial (CD): Mirikizumab superior to placebo, non-inferior to ustekinumab.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dosing and Onset of Action</strong></summary>
            <div>
                <ul><li>Risankizumab: 600mg IV @ weeks 0, 4, 8, then 360mg or 180mg SC every 8 weeks.</li><li>Mirikizumab: 300mg IV @ weeks 0, 4, 8, then 200mg SC every 4 weeks.</li><li>Relatively rapid onset of action: ≈13% achieve symptomatic remission, 33% experience significant clinical improvement w/in 2 weeks.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety</strong></summary>
            <div>
                <ul><li>Low rates of serious infection, MACE, &amp; malignancy in clinical trials.</li><li>Most common adverse events: upper respiratory tract infections, joint pain, injection site reactions, rash, headache, UTI.</li><li>Ustekinumab appears safer than TNF antagonists &amp; vedolizumab in CD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Special Situations</strong></summary>
            <div>
                <ul><li>Therapeutic drug monitoring: Risk of immunogenicity very low.</li><li>Pregnancy &amp; lactation: Reasonable to continue IL-23 antagonists during pregnancy.</li><li>Acute severe UC: Unlikely to be effective agents for inpatient use due to slower onset of action.</li></ul>
                
        <details>
            <summary><strong>Perioperative Management</strong></summary>
            <div>
                <ul><li>Limited data on safety in patients undergoing IBD-related surgery.</li><li>Rheumatology/orthopedic guideline: Delay elective joint surgery until next biologic dose is due, withhold next dose until wound healing.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Extraintestinal Manifestations</strong></summary>
            <div>
                <ul><li>Risankizumab &amp; guselkumab approved for psoriasis &amp; psoriatic arthritis.</li><li>Useful in patients w/ comorbid psoriasis or psoriatic arthritis w/ IBD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Sphingosine-1 Phosphate Receptor Modulators (S1PR Modulators)</strong></summary>
            <div>
                <ul><li>Etrasimod &amp; ozanimod: Oral S1P receptor modulators approved for moderate-severe UC.</li><li>Work by binding S1P receptor on immune cell surfaces, preventing immune cell trafficking.</li><li>Leads to fewer immune cells being transported to peripheral circulation &amp; target sites of inflammation.</li></ul>
                
        <details>
            <summary><strong>Effectiveness</strong></summary>
            <div>
                <ul><li>Ozanimod: Superior to placebo in achieving clinical remission, response, endoscopic improvement, &amp; mucosal healing.</li><li>Etrasimod: Higher rates of clinical remission, response, endoscopic improvement, &amp; endoscopic improvement-histologic remission vs. placebo.</li></ul>
                
        <details>
            <summary><strong>Ozanimod Details</strong></summary>
            <div>
                <ul><li>TRUE NORTH program: S1PR modulator targeting S1P1 &amp; S1P5.</li><li>Higher rates in biologic-naïve patients.</li><li>Referral center study: 53% achieved clinical remission by week 10, 25% @ week 52.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Etrasimod Details</strong></summary>
            <div>
                <ul><li>ELEVATE 12 &amp; ELEVATE 52 studies: S1PR modulator targeting S1P1, S1P4 &amp; S1P5.</li><li>Etrasimod more efficacious than placebo in achieving clinical remission &amp; endoscopic improvement.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Dosing and Onset of Action</strong></summary>
            <div>
                <ul><li>Ozanimod: &quot;Ramp up&quot; dose titration during first week, then 0.92mg daily.</li><li>Etrasimod: 2mg daily throughout induction &amp; maintenance, w/o dose titration.</li><li>Relatively slower acting due to mechanism focusing on lymphocyte sequestration.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Safety</strong></summary>
            <div>
                <ul><li>ALC decreases by ≈50% by week 10 w/ ozanimod, &amp; by week 2 w/ etrasimod.</li><li>Increased risk of infections, including shingles (VZV vaccination recommended).</li><li>Contraindicated in patients w/ recent history of MI, unstable angina, stroke, advanced heart failure, etc.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Special Situations</strong></summary>
            <div>
                <ul><li>Therapeutic drug monitoring: Not warranted given strong correlation between dose &amp; exposure.</li><li>Pregnancy &amp; lactation: Avoid during pregnancy &amp; breastfeeding.</li><li>Acute severe UC: Probably not suited for management of ASUC due to slower action.</li></ul>
                
        <details>
            <summary><strong>Perioperative Management</strong></summary>
            <div>
                <ul><li>Very limited data on safety in patients undergoing colectomy or other extra-intestinal surgery.</li><li>Ozanimod washout period: ≈55 days; etrasimod washout period: ≈1 week.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Extraintestinal Manifestations</strong></summary>
            <div>
                <ul><li>Ozanimod approved for multiple sclerosis.</li><li>May be preferred option for patients w/ UC &amp; comorbid multiple sclerosis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Positioning Modern Therapies in the Management of IBD</strong></summary>
            <div>
                <ul><li>Approach relies on integration of medication effectiveness &amp; safety in context of individual patient&#x27;s risk &amp; preferences.</li><li>Effective disease control w/ avoidance of corticosteroids is primary aim.</li><li>Goal of maintaining sustained remission &amp; avoiding disease complications.</li></ul>
                
        <details>
            <summary><strong>Crohn&#x27;s Disease</strong></summary>
            <div>
                <ul><li>Infliximab &amp; adalimumab: Most effective for induction in biologic-naïve patients, esp. w/ complicated phenotypes.</li><li>Ustekinumab &amp; risankizumab: Reasonable alternatives w/ superior safety profile in moderate luminal CD.</li><li>Risankizumab &amp; upadacitinib: Likely most effective therapies in patients w/ prior TNFα antagonist failure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ulcerative Colitis</strong></summary>
            <div>
                <ul><li>Upadacitinib: Most efficacious agent for most patients w/ moderate-severe UC.</li><li>Infliximab &amp; vedolizumab: Probably most efficacious therapies for induction in biologic-naïve patients.</li><li>S1PR modulators: Efficacious &amp; attractive first-line therapies as oral, small molecule drugs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Cost and Access Considerations</strong></summary>
            <div>
                <ul><li>Cost is major determinant of access to IBD therapies.</li><li>Patients w/ commercial insurance often eligible for manufacturer co-pay assistance programs.</li><li>Medicare prescription drug reform legislation caps patient out-of-pocket costs at $2000 annually in 2025.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
